MeSH D003424 - crohn disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biocon | Adalimumab | Hulio |  | 2020-07-06 |  |  |
| Johnson & Johnson | Infliximab | Remicade |  | 1998-08-24 | $1,653 M | Q2/23-Q1/24 |
| Ustekinumab | Stelara |  | 2009-09-25 | $10,865 M | Q2/23-Q1/24 | |
| Sandoz | Adalimumab | Halimatoz |  | 2018-07-26 |  |  |
| Adalimumab | Hefiya |  | 2018-07-26 |  |  | |
| Adalimumab | Hyrimoz |  | 2018-10-30 |  |  | |
| Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite |  | 2000-05-18 |  |  | |
| Infliximab | Zessly |  | 2018-05-18 |  |  | |
| Natalizumab | Tyruko |  | 2023-08-24 |  |  | |
| Methotrexate | Methotrexate |  | 2009-03-31 |  |  | |
| Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-08-25 |  |  |
| Organon | Alendronate, Cholecalciferol | Fosamax D |  | 2005-04-07 |  |  |
| AbbVie | Adalimumab | Humira |  | 2002-12-31 | $13,133 M | Q2/23-Q1/24 |
| UCB | Certolizumab pegol | Cimzia |  | 2008-04-22 |  |  |
| Pfizer | Adalimumab | Abrilada |  | 2019-11-15 |  |  |
| Adalimumab | Amsparity |  | 2020-02-13 |  |  | |
| Infliximab | Inflectra |  | 2013-09-10 | $490 M | Y2023 | |
| Infliximab | Ixifi |  | 2017-12-13 |  |  | |
| Takeda | Vedolizumab | Entyvio |  | 2014-05-20 |  |  |
| Rising Pharmaceuticals | Azathioprine | Azathioprine |  | 1999-12-13 |  |  |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
86%61/71
Phase 2
45%55/122
Phase 3
51%42/83
Approved: 16Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use